UPDATE: Citi Upgrades Zymeworks (ZYME) to Buy, 'Better Risk/Reward Has Emerged'

(Updated - January 28, 2021 7:01 AM EST)

Citi analyst Yigal Nochomovitz upgraded Zymeworks (NYSE: ZYME) from Neutral to Buy with a price target of $53.00.

The analyst comments "The direction of the market’s reaction to the ZW49 update does not come as a huge surprise as we had previously expressed caution that in view of the limited data (just 6 evaluable patients in the top two dose cohorts in the Q3W schedule) interpreting the ORR vs. competing therapies (Enhertu, Pfizer’s HER2 ADC PF-06804103) would likely be challenging. That being said, despite a somewhat confusing and even at times contentious Q&A session, we do not believe that the probability of success for ZW49 should be lowered from our current 60% assumption because safety looks very favorable at the go-forward expansion dose (Q3W 2.5mg/kg) and we simply don’t have enough information to properly evaluate efficacy. Therefore, given the stock is now trading at ~$33 in the post-market, we are upgrading ZYME to Buy and retaining our $53 price target in view of a more favorable risk/reward profile."

For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.

Shares of Zymeworks closed at $44.06 yesterday.

You May Also Be Interested In

• BMO Capital Upgrades SL Green Realty (SLG) to Outperform, 'NYC Is Back (Even Office)'
• Spotify (SPOT) PT Raised to $325 at Benchmark
• JPMorgan Upgrades JetBlue Airways (JBLU) to Neutral, 'second least-liked airline based on sellside rating'